MARKET

NEXI

NEXI

NexImmune, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.67
-1.31
-10.93%
After Hours: 10.25 -0.42 -3.94% 16:34 07/23 EDT
OPEN
12.00
PREV CLOSE
11.98
HIGH
12.51
LOW
10.53
VOLUME
30.80K
TURNOVER
--
52 WEEK HIGH
28.00
52 WEEK LOW
10.53
MARKET CAP
223.67M
P/E (TTM)
-7.2927
1D
5D
1M
3M
1Y
5Y
NexImmune Strengthens Management Team with Key Appointments
Dr. Jack A. Ragheb as Senior Vice President, Translational ScienceMatt Schiller, Head of Business Development GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel app...
GlobeNewswire · 07/14 20:01
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12)
Benzinga · 07/13 12:05
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 11:36
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6)
Benzinga · 07/07 11:41
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22)
Benzinga · 06/23 11:35
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21)
Benzinga · 06/22 12:12
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week, headlining the biotech news flow of the week.
Benzinga · 06/07 12:52
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Benzinga · 05/31 15:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NEXI. Analyze the recent business situations of NexImmune, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NEXI stock price target is 33.33 with a high estimate of 35.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 9.69M
% Owned: 46.24%
Shares Outstanding: 20.96M
TypeInstitutionsShares
Increased
0
0
New
46
9.69M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Sol Barer
President/Chief Executive Officer/Director
Scott Carmer
Chief Financial Officer/Primary Contact
John Trainer
Chief Operating Officer
Kristi Jones
Executive Vice President
Jerome Zeldis
Senior Vice President
Jack Ragheb
Other
Robert Knight
Other
Matt Schiller
Independent Director
Timothy Bertram
Independent Director
Paul D'Angio
Independent Director
Alan Roemer
Independent Director
Grant Verstandig
Independent Director
Zhengbin Yao
No Data
About NEXI
NexImmune, Inc is a clinical-stage biotechnology company. The Company is engaged in developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. The Company provides Artificial Immune Modulation (AIM) which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. Its T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. The Company’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation and multiple myeloma refractory to lines of therapy, respectively.

Webull offers kinds of Neximmune Inc stock information, including NASDAQ:NEXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEXI stock methods without spending real money on the virtual paper trading platform.